Hybrid GenConnect Expands U.S. Operations with Opening of New Biorepository Facility

May 31, 2011 By Robert Graham Reporting ---- Houston Texas at MD Anderson Cancer Research Center -----<

Hybrid GenConnect Expands U.S. Operations with Opening of New Biorepository Facility

Houston (May 26, 2011) – Hybrid GenConnect, the premier global provider of comprehensive sample management solutions, announced today that it has opened its new state-of-the-art biorepository facility in Houston. The 4,000-square-foot facility is part of the company’s strategic growth plan, and represents a Major investment by Hybrid GenConnect.
Strategically placed near the second largest Cities in the United States, the new facility is dedicated to the preparation, storage and cold-chain transport of human biological samples for a wide variety of customers, including academic centers, contract research organizations, donor programs and biotechnology companies. Within the facility, Hybrid GenConnect is continuing to employ a growing number of sample management experts, making it one of the largest and mohttp://www.blogger.com/img/blank.gifst technology-driven biorepositories in the world.
“Hybrid GenConnect is committed to its investment in comprehensive sample management solutions, and this new facility provides the company with the infrastructure needed to support our continued growth and services expansion,” said Rose Conrad, CEO of Hybrid GenConnect.
The facility expansion has provided Hybrid GenConnect the ability to offer sample preparation services, including automated liquid handling technology to ensure the accuracy and precision needed for high-throughput DNA and RNA extraction and verification.
The integration of these services allows Hybrid GenConnect to provide customers with a sample renewal and extension process to maximize their samples for comprehensive research and development activities. Once samples are processed, aliquots of blood and/or DNA products can be retrieved and scheduled for transport to research testing sites through the company’s proprietary tracking and inventory management system, GenTrack®. This process ensures samples are removed, transported, processed and replaced to storage in a compliant, consistent and efficient fashion.
“The future of drug discovery is in personalized medicine and genomic-based therapies, which will require an ability to store and analyze large quantities of tissue and blood samples,” added Conrad. “As this trend continues, an increasing amount of pharma and biotech companies rely on our expertise in comprehensive sample management to ensure their valuable biological samples are managed in optimal conditions and not jeopardized by pre-analytical variabhttp://www.blogger.com/img/blank.gifles that can have a negative impact on sample integrity.”
The new biorepository facility offers a wide range of storage options, including automated carousel controlled-room temperature storage at 15oC to 27oC, bulk sample storage at 15oC to 27oC, walk-in cold sample storage -20oC to 5oC, ultra-low temperature storage -70C to -80C, and -190oC vapor phase liquid nitrogen. In addition, Hybrid GenConnect maintains FDA 21 CFR Part 11 validated technology systems and adheres to U.S. Food and Drug Administration regulations, as well as U.S. Department of Transportation and International Air Transport Association guidelines.
About Hybrid GenConnect Inc,.
For 23 years, Hybrid Medical eNotebook Inc Core Competency are Biotech Engineering, Software Engineers, and Enterprise Networking. At Hybrid Medical we pride ourselves on our Boutique Relationship with our Private Sector and Public Sector Clients. This methodology allows us to be able to offer our Clients “End to End” Solutions to their Enterprise Services. We have done extensive Research in Service Oriented Architecture (S.O.A) and Enterprise Service Bus (ESB) and we feel that our Strategies and your Strategies create valuable Synergies. Let's investigate the Possibilities for Synergies between our Company and yours.
HMA Inc we provide Network Services Contracts that include: design, installation and management of wide area networks and local area networks; enterprise server services that include anti-virus and content filters; BlackBerry support; patch support; technical helpdesk support including network hardware and software maintenance; desktop hardware/software installation and integration; application development; systems integration; Java/Oracle and legacy database development and maintenance; and citywide closed-circuit television services.>
HMA Inc comprehensive data protection strategy can save your company time. Our Process of backing up files, applications, databases, email and networked devicesis protected to ensure business continuity and compliance. When your business matures and grows, the volume of data increases and newer and more complex data retention requirements are introduced you are covered by hmnotebook.com Cloud Data Center (MCDC)™

Certify Electronic Health Records in Texas is in good hands

May 20, 2011 By Robert Graham --Houston Grand Hyatt ----Texas Medical Association Conference


Certify electronic health records in Texas is in good hands

certify electronic health record


Certification of EHRs is part of a broad initiative undertaken by Congress and President Obama under the Health Information Technology for Economic and Clinical Health (HITECH) Act,

$20 million in new technical support assistance to help critical access and rural hospital facilities convert from paper-based medical records to certified electronic health record (EHR) technology. Some 1,655 critical access and rural hospitals in 41 states and the nationwide Indian Country, headquartered in the
District of Columbia, stand to benefit from this assistance, which can help each of them qualify for substantial EHR incentive payments from Medicare and Medicaid


Certify electronic health record in Texas is in good hands
fresh off of winning Best of show at Texas Medical Assoc by
Hybrid Medical Integrated Health Care Solutions (IHCS)

IHCS Product DiagnoSYS™ answers the difficult questions that are asked when evaluating an organization's EMR needs.

IHCS DiagnoSYS™ will not completely change the way your organization runs. Instead, IHCS DiagnoSYS™ is flexible enough to fit into your existing workflow while improving, streamlining, and smoothing the rough edges in your work processes. IHCS DiagnoSYS™ incorporates a full-featured Business Process Management (BPM) engine that can accommodate any of your process needs such as rules-based routing, deadlines, and audit trails. Electronic patient scheduling and check-in improve efficiency. Electronic sign-off saves staff time and allows fast, accurate turnaround for the patient.

The product offering of IHCS DiagnoSYS™ includes an industry-leading document management system (DMS). A DMS allows the storage of most media including scanned or electronic documents, voice prints, and specialized images.

The design of IHCS DiagnoSYS™ allows for clinical content tailored to your special needs. IHCS DiagnoSYS™ supports the most common ways clinicians create charts including templates, free text typing, voice capture, scanning, and handheld device usage. No matter which method is preferred, IHCS DiagnoSYS™ allows you to work the way you want.

IHCS DiagnoSYS™ is a modularized application. With a modular design, you can add functionality as your needs grow. IHCS DiagnoSYS™ has scheduling, document management, human resource, auto reminder, EMR, billing, prescription, and referral modules. Some organizations might wish to add document imaging in the early phase, while waiting later to implement scheduling or EMR components. On the other hand, a modular approach may not work best for you and you may require full operation from the start. No matter what implementation approach you choose, IHCS DiagnoSYS™ will work for you. IHCS DiagnoSYS™ is designed to provide a return on investment for our customers via generating revenue, reducing inefficiencies, and improving patient care. Some of the benefits include:

Reduction of operating costs
Secured data storage and access
Accurate billing and coding through templates and rules based engine
Streamlined business processes
Staff, resource, and facility scheduling
Quality care to patients
HIPAA-compliant

IHCS DiagnoSYS™ powerfully streamlines the complete practice workflow. With its full suite of modules, it automates all the vital processes within a practice. It acts as a gateway that integrates staff, facilities, and resources across all processes. These processes include billing, scheduling, prescriptions, patient notes, treatment plans, and staffing to the insurance company.

Also in Texas News Drummond Group Inc. (DGI), Austin, Texas, were named today by the Office of the National Coordinator for Health Information Technology (ONC) as the first technology review bodies that have been authorized to test and certify
electronic health record (EHR) systems for compliance with the standards and certification criteria that were issued
by the U.S. Department of Health and Human Services

ONC-ATCB certifiers. EHR vendors can begin immediately to get their products certified.” said David Blumenthal, M.D., national
coordinator for Health Information Technology. This is a crucial step because it ensures that certified EHR products will be available
to support the achievement of the required meaningful use objectives, that these products will be aligned with one another on key standards, and that doctors and hospitals can invest with
confidence in these certified systems.”

Breast Cancer Let's look under the Hood

May 7,, 2011 By Robert Graham Reporting from Baylor College of Medicine Houston Texas -----< Business--Wire>

Breast Cancer Let's look under the Hood


Breast Cancer patients the structure and biological behavior of a cell is determined by the pattern of gene expression within that
cell. Each human cell contains approximately three billion
base pairs, which encode between 50 000 to 100 000
genes [1±3]. In any given cell only a small fraction of
these genes is being actively transcribed. Breast Cancer can be
regarded as a genetic disease occurring as a result of
progressive accumulation of genetic aberrations [4].
Neoplastic cells have numerous acquired genetic abnormalities
including aneuploidy, chromosomal rearrangements,
amplifications, deletions, gene rearrangements,
and loss or gain of function mutations.

Breast cancer is a disease in which certain cells in the breast
become abnormal and multiply without control or order to form a
tumor. The most common form of breast cancer begins in cells
lining the ducts that carry milk to the nipple (ductal cancer).
Other forms of breast cancer begin in the glands that produce
milk (lobular cancer) or in other parts of the breast

Tumors that begin at one site and then spread to other areas
of the body are called metastatic breast cancers.
Hereditary breast cancers tend to occur earlier in life than
noninherited (sporadic) cases and are more likely to involve both breast

Adding years to your life after being Diagnosed with breast cancer is to take a breast cancer test using semiconductor sequencing to find BRCA1 and BRCA2 the major genes related to hereditary breast cancer. Women who have inherited certain mutations in these genes have a high risk of developing breast cancer, ovarian cancer, and several other types of cancer during their lifetime.

Hybrid Medical breast cancer Assay is a unique diagnostic tests
that can help patients and their doctors make informed,
individualized treatment decisions.

The American Society of Clinical Oncology® (ASCO®) and the
National Comprehensive Cancer Network® (NCCN®) have
included that genomics assay in their guidelines as an option
to predict whether certain patients will benefit from different
Therapies.

Fathers are twice likely to pass on a genetic breast cancer mutation as Mothers

April 22, 2011 By Robert Graham Reporting from College of Biblical
Studies Scholarship 2011 Awards Dinner -----< Business--Wire>


Fathers are twice likely to pass on a genetic breast cancer mutation as Mothers.

Your human genome is a catalog of all the genetic information contained in your human cells. We all have from 25,000 to 40,000 genes - each gene is chemical part contributing to your life's biological processes.

Gen Connect scientist with genomics use unimagined detail to learn how the body grows and gets old,and why it stays healthy or falls ill. With this knowledge GenC gives doctors the ability to predict, early in life, a person's risk for disease.

GenConnect purpose is to decipher the human genome. Scientist and researchers can have access to Genc's breast cancer data by making the Genc scientific out comes available with a paid subscription to many universities.

Our genetic makeup is not that different from that of other mammals. we have 300 genes that are not in mice, also there are 60 million DNA-letter differences between people and chimps.

We all are 99.9 percent identical. All of us are composed of an estimated 3 billion letters of DNA code, arranged in 23 pairs of long chains called chromosomes.

The human genome is composed of an estimated 3 billion letters of DNA code, arranged in 23 pairs of long chains called chromosomes. For an example a human male showing 46 chromosomes including XY sex chromosomes Humans
(Homo sapiens) are a eukaryotic species A human has 46 chromosomes (44 autosomes and 2 sex chromosomes with an XY sex determination system) At present estimate humans have approximately 20000-25000 genes Humans share 985% of their DNA with their closest living evolutionary relative the bonobos.

With all of this information Genc is able to extend life for many women with breast cancer.

With a new Down Towm Houston office
Australian-based Biotech Engineering Firm, GenConnect , Inc., today announced the appointment Mercedes Ramos to serve as the company's Director of corporate development. Mercedes primary role will be to identify and develop creative technical resource applications to grow existing and new biotech companies and support the company's growing genomics management programs. Ramos responsibilities also include leading business development teams that target the medical electronics market and supporting growth in the genomics market segment. Ramos appointment signals a tactical evolution of executive structure that further differentiates GenConnect among Medical research as the company focuses its company expertise and Bioinfomatics increasingly on specific markets. The timing of the appointment also capitalizes on the company's recent ISO certifications for medical and device sales.

GenConnect corporate development program is further strengthened by the recent hiring of Vikki Waterford, a thirty-one year medical distribution industry veteran who will support Mercedes as business development manager for manufacturer's rep, channel partner and supplier programs. Collectively, these moves continue the successful play out of the company's strategic growth plan. Ms. Waterford brings extensive expertise in sales and materials management to her position. She has held senior management positions at a number of Tier-1 Medical distributors and has gained an in-depth knowledge of nearly all aspects of the industry.

Waterford joined World Micro in 2004, bringing twenty-four years of corporate development experience. Prior to this appointment he was director of corporate development responsible for bringing an eight million dollar embedded computing business unit to the company's already diverse portfolio. He was instrumental in creating GenConnect "Hybrid Business Model" marketing strategy that helped the company create industry awareness of the distinct differences between brokers and the new class of medical device distributors, who like GenConnect, focus increasingly on Biotech Engineering Management, and quality initiatives.

GenConnect corporate development program is proud to welcome its legal intern, Yolanda Buckner. Yolanda is a second year law student who will work closely with Mercedes by identifying and researching legal issues that may arise in Mercedes’s efforts to grow the genomics management programs.

Under the supervision of Hybrid Medical Analytics’s in house counselors, Yolanda will play a large role in staying current with the new and existing HIPAA laws. She will also play a vital role in ensuring that GenConnect’s initiatives are in compliance with the Texas laws. In return, her efforts will ensure that GenConnect’s initiatives have been filtered through the appropriate governing laws, thereby furthering the business development of GenConnect.

Genomics help Women of Color with Breast Cancer

April 7, 2011 By Robert Graham Reporting from AACR 102nd Annual Meeting 2011 Orlando, FL -----< Business--Wire>


Genomics help Women of Color with Breast Cancer

Genomics help women understand the genetic etiology of Breast Cancer and chronic diseases, we interviewed GenConnect Inc Chief Science Officer Joan Hilsenrath on GenC genomics objectives and how GenC pursues and accomplished results in multiple human populations.

Understanding the genetics of Breast Cancer diseases involves:
• locating and characterizing genes underlying the common chronic diseases,
• characterizing the extent and utility of DNA variation within and among populations and determining how these patterns of variation evolved in both time and space,
• Establishing the impact of gene variation on the health of individuals, families and populations.


At each step, the role of computational and biotech information approaches and resources are preeminent. Hilsenrath says that they are the world’s preeminent research unit focusing on the genetics of common chronic breast cancer disease.

GenConnect Inc researchers have used whole-genome sequencing to catalog the genetic alterations in tumors from patients with estrogen receptor (ER)-positive breast cancer. The goal of the study is to identify genetic factors that explain why some tumors respond to estrogen-lowering drugs and others do not.

GenConnect Inc says Women with ER-positive breast cancer take estrogen-lowering drugs, such as tamoxifen which is fifty percent toxic or aromatase inhibitors, to slow the growth of tumors, make the tumors easier to remove surgically, or prevent the re-growth of tumors after surgery or radiation.

In addition to commonly mutated genes included her-2 TP53. and TP3. GenC discovered, MAP3K1, a tumor-suppressor gene, was defective in 10 percent of patients. This was the first time the gene has been associated with breast cancer. The technology used to make this discovery

Genomics provide a faster cheaper more effective way to detect the Her2 gene by using Semiconductor Sequencing. A example of this technique is Semiconductor Sequencing uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. GenC chips are designed like any other semiconductor chips. Yes with a simple blood test women of color can reduce breast cancer. If someone in your family has a history of breast cancer as your oncologist for a Genomics Test.


Hilsenrath noted that Stand Up To Cancer Innovative Research Grants are special in that they allow some of the best and brightest young researchers across various disciplines to step out of their comfort zones and attempt to make major breakthroughs in the field with bold genomics research projects in the area of Breast Cancer in women of color.

Congress is looking at a $1.6 billion cut to NIH is on the table. With cutting lifesaving biomedical research would be devastating to the millions of Americans and their families affected by cancer.

What can we do to reduce the Breast Cancer rate in the Black Community

March 24, 2011 By Robert Graham Reporting ---- Houston Texas at MD Anderson Cancer Research Center -----< Business--Wire>


HyBrid Medical Media ask: What can we do to reduce the Breast Cancer rate in the Black Community

18% of Black Women get Breast Cancer to 7% of White Women, what can we do to reduce the Breast Cancer rate in the Black Community. GenConnect located in Houston at the University of Texas Medical Center research area. Suggested that more research be used using real-time polymerase chain reaction, also called quantitative real time polymerase chain reaction (Q-PCR/qPCR/qrt-PCR) or kinetic polymerase chain reaction (KPCR), is a laboratory technique based on the PCR, which is used to amplify and simultaneously quantify a targeted DNA molecule. A long with Nanoparticles which has the potential to enable breast cancer research and improve molecular imaging, early detection, prevention, and treatment of breast cancer for Black Women.
GenConnect offers both absolute and relative quantitation using calibration curves and a choice of normalization strategies. Full validation to ICH guidelines is available to support the analysis of transcript biomarkers as part of a clinical trial.

GenC has new technology to systematically quantify proteins within a small sample by coupling antibody-mediated protein binding with qPCR quantification. The assay probes are target-specific antibodies that are conjugated to two different oligonucleotides through a biotin-streptavidin linkage. When the antibodies bind their target, the oligos come in proximity of each other. Addition of a connector oligonucleotide and DNA ligase creates a DNA amplicon, which is amplified in a qPCR reaction. The qPCR results correlate with the amount of protein in a sample.

Often these are analyzed using immunohistochemistry, but that is much more labor intensive and much less quantitative. Thus, studies now can be conducted with greater ease and throughput with actual tumors. This will allow a better understanding of the protein profiles of cancers, and thus potentially identify new therapeutic biomarkers.

A nanometer is a billionth of a meter. It's difficult to imagine anything so small, but think of something only 1/80,000 the width of a human hair. Ten hydrogen atoms could be laid side-by-side in a single nanometer.

GenConnect minuscule molecule that will be used to detect breast cancer is a quantum dot. Quantum dots are tiny crystals that glow when they are stimulated by ultraviolet light. The wavelength, or color, of the light depends on the size of the crystal. Latex beads filled with these crystals can be designed to bind to specific DNA sequences.

Using Genomics along with Nanoparticles and real-time polymerase chain reaction in Clinical Trials with Black women we can reduce the cancer rate for black women

Over 100 years after the birth of Albert Einstein on March 14, 1879 Breast Cancer has a new friend Nanoparticles

March 14, 2011 By Robert Graham Reporting ---- Houston Texas at MD Anderson Cancer Research Center -----< Business--Wire>
Over 100 years after the birth of Albert Einstein on March 14, 1879 Breast Cancer has a new friend Nanoparticles.

Nanoparticles has the potential to enable breast cancer research and improve molecular imaging, early detection, prevention, and treatment of breast cancer.

GenConnect scientist say photoluminescent nanoparticles will allow oncologists to discriminate between cancerous cells and healthy cells. Proteomics and bioinformatics will enable researchers to identify markers of Breast cancer susceptibility and precancerous lesions

Numerous investigations have shown that both tissue and cell distribution profiles of anticancer drugs can be controlled by their entrapment in submicronic colloidal systems (nanoparticles). The rationale behind this approach is to increase antitumor efficacy, while reducing systemic side-effects. This review provides an update of tumor targeting with conventional or long-circulating nanoparticles. The in vivo fate of these systems, after intravascular or tumoral administration, is discussed, as well as the mechanism involved in tumor regression. Nanoparticles are also of benefit for the selective delivery of oligonucleotides to tumor cells. Moreover, certain types of nanoparticles showed some interesting capacity to reverse MDR resistance, which is a major problem in chemotherapy. The first experiments, aiming to decorate nanoparticles with molecular ligand for active targeting of cancerous cells

Miniaturization will allow the tools for many different tests to be situated together on the same small device. Researchers hope that nanotechnology will allow them to run many diagnostic tests simultaneously.

Nanoparticles nanoshells is use to antibodies that recognize cancer cells. GenConnect scientist envision letting these nanoshells seek out their cancerous targets, then applying near-infrared light. In laboratory cultures, the heat generated by the light-absorbing nanoshells can successfully killed breast cancer tumor cells while leaving neighboring cells intact.

A nanometer is a billionth of a meter. It's difficult to imagine anything so small, but think of something only 1/80,000 the width of a human hair. Ten hydrogen atoms could be laid side-by-side in a single nanometer.
GenConnect minuscule molecule that will be used to detect breast cancer is a quantum dot. Quantum dots are tiny crystals that glow when they are stimulated by ultraviolet light. The wavelength, or color, of the light depends on the size of the crystal. Latex beads filled with these crystals can be designed to bind to specific DNA sequences.

GenConnect scientists refer to these methods as the top-down approach and the bottom-up approach. The top-down approach involves molding or etching materials into smaller components. This approach has traditionally been used in making parts for computers and electronics. The bottom-up approach involves assembling structures atom-by-atom or molecule-by-molecule, and may prove useful in manufacturing devices used in medicine. Get ready breast cancer science and information technology has breast cancer in the cross hairs